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1. ABSTRACT 
The number of people suffering from age-related neurodegeneration has been estimated 
to quadruplicate by the year 2050; being Alzheimer’s disease (AD) the most common 
dementia in the western world in elderly people. AD has a great impact not only in 
patients and in their families, but also for the society due to the enormous health-care 
costs. First diagnosed in 1907 by Alois Alzheimer, AD is characterized by the loss of 
short-term memory, the negation of this loss, language difficulties and behavioral 
changes; although these changes can be sometimes difficult to distinguish from the 
normal forgetfulness in aging. The etiology is heterogeneous, with both genetic and 
environmental factors. In the pathogenesis of AD neuropathological changes (abnormal 
accumulation of harmful proteins) and in neurotransmitters (producing synaptic failure), 
oxidative stress, mitochondrial dysfunction and inflammation are present. Up to now, 
neither biomarkers for an early diagnosis nor effective treatments are available; 
therefore, prevention is the best strategy to delay the onset of the disease. In the last 
years, accumulating evidence sustains that diet can be an important factor in maintaining 
brain health. In fact, the Mediterranean diet is associated with a reduced risk of age- 
related cognitive impairment, and olive oil, a staple food of this dietary pattern, could 
have a pivotal role in the prevention of AD. In this sense, the phenolic content present in 
olive oil has been proposed as the main responsible for the preventive effects of this 
food, since many in vitro and in vivo studies have indicated that they act in multiple steps 
of the pathogenesis of AD. The present work reviews the data on the bibliographic 
supporting this hypothesis. 
 
RESUM 
 
El nombre de persones que pateixen neurodegeneracions relacionades amb l'edat 
s’estima que es quadruplicarà l'any 2050; sent, la Malaltia de l’Alzheimer (MA) la forma 
més comuna de demència al món occidental en persones d'edat avançada. La MA té un 
gran impacte no només en els pacients i en les seves famílies, sinó també per a la 
societat a causa dels enormes costos d’atenció sanitària. Diagnosticada per primera 
vegada al 1907 per Alois Alzheimer, la MA es caracteritza per la pèrdua de memòria a 
curt termini, la negació d'aquesta pèrdua, les dificultats de llenguatge i canvis de 
comportament; tot i que aquests canvis poden ser de vegades difícils de distingir de la 
pèrdua habitual de memòria de la gent gran. L'etiologia és heterogènia, amb factors 
genètics i ambientals. En la patogènesi de la MA s’hi ha descrit canvis neuropatològics 
(acumulació anormal de proteïnes perjudicials) i en els neurotransmissors (produint 
fracàs sinàptic), estrès oxidatiu, disfunció mitocondrial i inflamació. Fins ara, no s’han 
descrit marcadors de diagnòstic precoç ni cap tractament eficaç; per això, la prevenció 
és la millor estratègia per a retardar l’inici de la malaltia. L'evidència acumulada dels 
darrers anys sosté que la dieta pot ser un factor important en el manteniment de la salut 
del cervell. De fet, la dieta mediterrània s'associa amb un menor risc de deteriorament 
cognitiu relacionat amb l'edat, i l'oli d'oliva, un aliment bàsic d'aquest model 
d'alimentació, podria tenir un paper fonamental en la prevenció de la MA. En aquest 
sentit, el contingut fenòlic present a l'oli d'oliva s'ha proposat com el principal 
responsable dels efectes preventius de l'oli d'oliva, ja que molts estudis in vitro i in vivo 
han indicat que actuen en múltiples etapes de la patogènesi de la MA. El present treball 
revisa les dades a la bibliografia que donen suport a aquesta hipòtesi. 
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2. INTRODUCTION 
 
With the increase in life expectancy of human society, there is a greater incidence of 
age-associated diseases, including Alzheimer’s disease (AD). Therefore, very strong 
efforts are being made to investigate the exact alterations that take place in this 
pathology with the purpose to find reliable markers for an early diagnosis and effective 
therapies or, at least, treatments suitable to delay the manifestations of clinical signs (1). 
Up to now, prevention is still the best strategy to combat AD (2); an increasing interest 
for alternative options in the prevention and treatment based in plants aiming to combine 
efficacy with safety is rising up (3). 
AD was first described in a 55 year old woman in Germany in 1907 by professor Alois 
Alzheimer, psychiatrist and neuropathologist. At first, the illness was thought to be a 
relative strange way of presenile dementia because the patient suffered from psychiatric 
symptoms with cognitive impairment, but at necropsy there were found plaques, 
neurofibrillary tangles (NFTs) and arteriosclerotic changes which nowadays are clear 
sings of AD (4). 
AD has an insidious onset, sometimes difficult to distinguish from the usual forgetfulness 
that takes place in aging. When the first clinical manifestations appear, the pathogenesis 
of the disease is already in an advanced stage. AD originates from the abnormal 
accumulation of harmful proteins in the nervous system. These consist of β-amyloid (Aβ) 
peptide, the lipid-carrier protein apolipoprotein E (apoE), the microtubule associated 
protein tau and the presynaptic protein α-synuclein (which is also involved in Parkinson’s 
disease). Aβ peptide, apoE, tau and α-synuclein interact with a lot of molecules that 
modulate diverse signaling cascades regulating neuronal activity and survival (5). These 
accumulations of harmful proteins in the nervous system produce failures in the neural- 
network activity and impair synapses between neurons that create and keep 
microcircuits supporting learning and memory. This eventually causes atrophy and death 
of neurons in a process that can include excitotoxicity (overstimulation of 
neurotransmitter receptors on neuronal surface membranes), collapse of calcium 
homeostasis producing synaptic failure, inflammation, mitochondrial dysfunction and 
oxidative damage (5). Microscopically, the protein abnormalities cause cerebral plaques 
laden with Aβ peptide, dystrophic neurites in the neocortical terminal fields and prominent 
NFTs in the medial temporal lobe (6). 
From a clinic point of view, AD usually appears with a subtle lack of memory that can be 
associated with normal aging followed by a slow but progressive dementia that lasts 
several years. Anatomopathologically, there is a diffuse and manifest atrophy of the 
cerebral cortex, with secondary enlargement of the ventricular system (6). 
Although the etiology of AD is not very clear, multiple genetic and environmental factors 
had been identified, such as family background, advanced age, gender, diabetes and 
exposure to toxicants among others. As some modifiable lifestyle-related factors are 
associated with cognitive decline, diet has become an object of intense research in 
relation to cognitive aging and neurodegenerative diseases. It has been seen that a 
higher adherence to the Mediterranean Diet (MD) is not only associated with a lower 
prevalence and incidence of chronic diseases, as cardiovascular disease, cancer, 
metabolic syndrome and diabetes, but also is associated with a reduced cognitive 
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decline (7). As olive oil is an ingredient never absent in this diet, the beneficial effects 
towards the neuroprotective effect were associated during a lot of time to its major 
component: the unsaturated lipids, particularly oleic acid. However, now the antioxidant 
phenolic content in olive oil is thought to be the main component responsible for the 
reduced risk of age-related cognitive impairment (8). 
Thanks to the continuing efforts of researchers, more and more natural compounds are 
being identified that can hit multiple targets implicated in AD thanks to the growing 
awareness of the pathological processes that take place in the disease. In fact, clinical 
and epidemiological studies have shown that nutritional components with antioxidant 
properties, such as polyphenols in olive oil, exert protective effects against 
neurodegenerative disorders (9). 
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3. OBJECTIVES 
 
Alzheimer’s disease has a great repercussion and will continue to have it in the next 
years as its incidence and prevalence will continue to grow. Moreover, it has an insidious 
onset and when clinical signs emerge the pathogenesis is already in an advanced stage; 
at the present, early diagnostic biomarkers and effective therapeutics are missing. For 
these reasons, the present review will aim to answer the following objectives: 
i. Describe Alzheimer’s disease epidemiology, definition, differences with 
normal aging, clinical manifestations and etiology. 
ii. Analyze the pathogenesis, diagnostic and treatments for Alzheimer’s 
disease. 
iii. Study the possibility of non-pharmacological approaches to combat 
Alzheimer’s disease. 
iv. Assess the potential effect of the Mediterranean diet in the 
neuroprotection of Alzheimer’s disease. 
v. Describe the composition of olive oil and study the major polyphenols 
present in it. 
vi. Establish the relation between Alzheimer’s Disease pathogenesis and 
where do polyphenols act in this process. 
vii. Review the most important epidemiological studies in humans with olive 
oil phenols. 
viii. Draw conclusions from the studied objectives. 
3.1. INTEGRATION OF THE FIELDS OF STUDY 
This study has been developed in a way that integrates three different fields of study of 
the Pharmacy degree: physiology and physiopathology, as the main scope and, 
pharmacology and therapeutics and nutrition and bromatology as secondary disciplines. 
The principal field of study is physiology and physiopathology as this work describes all 
the aspects related to the disease. Definition, first ever diagnosed case, multiple risk 
factors for developing the disease, clinical manifestations in the different stages, 
differences between “normal cognitive aging” and “memory and cognition disorders” and 
the pathologic mechanisms that occur during Alzheimer’s disease in the brain are 
developed in this work. 
Pharmacology and therapeutics has been integrated in the development of this 
dissertation because even though Alzheimer’s disease does not have an effective 
treatment, there are some drugs capable to slow down its progress. Groups of treatment, 
mechanisms, pharmacokinetics, daily doses and adverse effects of drugs used 
nowadays are going to be considered in the present work. 
Last but not least, nutrition and bromatology is also an important field of study in this 
work. With the support of the actual evidence, this work has considered the 
Mediterranean Diet as an approach to prevent Alzheimer’s disease development. Olive 
oil composition is described and olive oil polyphenols beneficial properties in the 
pathogenesis of the disease are reviewed. 
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4. MATERIAL AND METHODS 
 
To achieve the proposed objectives an extensive literature research has been conducted 
through primary and secondary bibliographical sources present in the PubMed and Web 
of Science databases and in books of pathological anatomy (10), of internal medicine 
(6,11) and drug catalogues (12). 
A first general search was done through PubMed to focus in which neurodegenerative 
disease this study would be centered. The diseases considered were Alzheimer’s 
disease, Parkinson’s disease and Huntington’s disease. According to the results of this 
first search, Alzheimer’s disease is the most studied in relation to the neuroprotective 
effect of olive oil polyphenols; for this reason, it was the disease chosen to develop the 
present study. 
Books have been used to understand the basis of Alzheimer’s disease physiopathology, 
differences with normal aging, clinical manifestations in every stage and current 
diagnosis. The official webpage of Alzheimer’s association (13) and other validated ones 
were also consulted. 
After a first and general idea of the disease, journal articles obtained from PubMed and 
Web of Science were used to develop the study up to May 2017. The information 
obtained was used to complement the basis of Alzheimer’s disease and to study the 
Mediterranean Diet and its one ingredient never absent: olive oil. Olive oil composition, 
its polyphenols and the steps of the pathogenesis where these compounds act have 
been treated in the present review. 
The exact search dates were from 1997 to 2017 with no restriction of language using the 
terms in the title/abstract of: “hydroxytyrosol” OR “tyrosol” OR “oleuropein” OR 
“oleocanthal” OR “olive oil polyphenols” OR “olive oil” AND “Alzheimer’s Disease” OR 
“neurodegenerative disease” OR “aging”. The search done looked for experimental and 
human studies evaluating the effect of olive oil polyphenols in neurodegenerative 
diseases, especially Alzheimer’s disease with the idea of providing evidence for health 
claims. 
6 
 
Results and Discussion 
  
 
5. RESULTS AND DISCUSSION 
 
5.1. ALZHEIMER’S DISEASE EPIDEMIOLOGY 
 
Dementias are a progressive deterioration in several cognitive domains that are severe 
enough to interfere with daily functions (7). Alzheimer’s disease (AD) is the most 
common way of dementia in the Western societies in elderly people, as its incidence 
increases with age (mostly through the 7th and 8th decades of life). The United Nations 
estimates that the number of people suffering from age-related neurodegeneration is as 
high as 25 million and is predicted to be quadrupled by the year 2050 (14). Approximately 
a 70% of these cases of neurodegeneration are attributed to AD. The highest prevalence 
(all the subjects suffering from the disease, independently of the contraction date) and 
incidence (number of new cases in a specific period of time) rates are in decreasing 
order for the populations from North America, Western Europe, Latin America, China, 
Western-Pacific regions and Africa (14,15). 
Vascular dementia is the second most common cause of dementia in old people; it is a 
loss of cognitive function because of ischemic, hypoperfusive or hemorrhagic brain 
lesions due to cerebrovascular disease or cardiovascular pathology. The combination of 
AD and vascular dementia is called mixed dementia (7). 
It must be taken into consideration that this disease does not only affect patients and 
their families, but also has a high repercussion on society, as the monthly overall mean 
cost of AD dementia in Spain is of 1,412.73 euros per patient every month (16) and only 
in the United States causes an estimated health-care cost of $ 172 billion per year (14). 
In fact, AD is the third most costly disease (17). 
 
5.2. DIFFERENCES BETWEEN “NORMAL COGNITIVE 
AGING” AND “MEMORY AND COGNITION DISORDERS” 
Before starting with the description of the development of the disease, a concept that is 
important to clarify is the fact that people suffer through life a normal and slow but 
progressive deterioration of memory that is not considered dementia. For this reason, is 
important to distinguish between "normal cognitive aging" and “disorders of memory and 
cognition” (11). 
Differentiate normal age-related changes with signs of AD can be difficult sometimes for 
two main reasons: first of all, because changes may be subtle sometimes and secondly, 
because as everyone is different so are the symptoms they may experience (18). 
In normal cognitive aging, short-term memory is usually well preserved; in contrast, there 
are impairments related to long-term memory. Memory problems reflect a decrease in 
the efficiency of both the information being processed and the information being 
retrieved, with a bigger deterioration in the processes of recovering memory than in the 
coding ones (11). 
Even though memory loss is a common symptom in all types of dementia, memory loss 
does not necessarily mean dementia. Dementia is diagnosed when two or more brain 
functions - such as memory and language skills – are deteriorated significantly without 
the loss of consciousness. There are some disorders that can cause dementia-like 
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symptoms without having dementia, such as: depression, drugs with anticholinergic 
activity, endocrine abnormalities (as hypothyroidism), nutritional deficiencies, brain 
tumors, anoxia or hypoxia (when the oxygen supply of the brain is reduced or cut 
entirely), decreased vision and hearing and heart and lung problems (11). 
On the other hand, non-normative cognitive decline is caused by any disorder that 
permanently damages large areas of association in brain hemispheres or subcortical 
areas that affect memory and learning (11). According to the National Institute of 
Neurological Disorders and Stroke, dementia is not a specific disease: it is a descriptive 
term that includes a collection of symptoms that are caused by a series of disorders that 
affect the brain. People with dementia have a significant impairment in intellectual 
functioning that interferes with normal activities and relationships; they lose their ability 
to solve problems and maintain emotional control and may suffer personality changes 
and behavioral problems (as agitation, delusions and hallucinations). Therefore, 
although dementia is common in old people, it is not a normal part of the process of aging 
(19). 
Another difference between these concepts is that even though in both normal brain 
aging and in AD dementia neuritic plaques and NFTs are present, in normal aging they 
accumulate in small amounts whereas in AD they do so in excess (6). 
 
5.3. ALZHEIMER’S DISEASE CLINICAL MANIFESTATIONS 
 
AD follows an insidious and progressive course with an average of survival from 8 to 10 
years after the diagnosis. It is characterized by the loss of short-term memory and the 
negation of this loss, language difficulty and behavioral changes (such as loss of sense 
of humor and social isolation) (6,11). 
AD develops in three general stages: early, middle and late (sometimes referred as mild, 
moderate and severe). However, not every person progresses through the same stages 
in the exact way (20). 
The initial changes are subtle; sometimes difficult to distinguish from the habitual 
forgetfulness of adults, but in AD these cognitive problems interfere with the daily routine. 
There is loss of short termed memory (such as forgetting recent conversations or names) 
and slight personality changes (like apathy) (6,11,18,20). 
As the disorder progresses, the disease gets to the moderate stage. It is typically the 
longest stage, as it last for several years, and it is characterized by a more general 
deterioration of the cognitive functioning; changes in the superior cortical functioning 
(that affect the resolution of problems and the spatial relations), extreme confusion, 
disorientation and lack of capacity to make daily activities. Depression also may appear 
in patients aware of their deficits (6,11,20). 
In the last stage patients are unable to react to the environment: they have difficulties in 
speaking, swallowing and walking (18). They also may suffer hallucinations and delirium. 
Uninhibited and aggressive behavior is alternated with passivity and social isolation. 
They require total cares and spend most part of time in bed, as they turn rigid, mute and 
incontinent. Death finally occurs usually due to malnutrition, secondary infections as 
pneumonia or heart disease (6,11). 
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The reason why the initial symptoms are only related to memory and as the disease 
progresses, they expand to many others is due to the fact that the first neurons damaged 
are usually in brain regions involved in creating new memories; yet, as neurons in other 
parts of the brain are destroyed, individuals experience other complications (18). 
 
5.4. ALZHEIMER’S DISEASE ETIOLOGY 
 
AD is caused by multiple factors, both genetic and environmental; it is likely that AD 
predisposing genes interact with other disease genes and environmental factors leading 
to the development of the illness (5). 
5.4.1. Family background 
Even though AD can be inherited only a small number of patients (probably less than 
1%) have early-onset AD (when signs and symptoms develop before 65 years old, it has 
a more rapid rate of progression). This is because they need to have inherited autosomal 
dominant mutations in genes whose protein products — amyloid precursor protein 
(APP), presenilin 1 or presenilin 2 — are involved in the production of Aβ peptides (5,14). 
In contrast, mutations on tau proteins do not occur in AD, but are present in other types 
of dementia (10). 
The most powerful genetic risk factor for AD is the ApoE ε4 allele, which encodes the 
ApoE4 lipid carrier that reduces the age of appearance of the illness by 6 to 7 years. 
However, the more common ApoE ε3 and the rare ApoE ε2 forms of ApoE are relatively 
protective against AD. The inheritance of the ApoE ε4 allele is also associated with a 
lower cognitive performance and mild cognitive impairment (MCI, an intermediate stage 
of cognitive deterioration in which functional independence is preserved but there is 
impairment in one or more cognitive areas; it is a good label for people that are at high 
risk of developing AD). However, the presence of this allele is neither necessary nor 
sufficient for developing the disease (5,14). 
5.4.2. Advanced age 
Ageing is the most important risk factor for AD. Ageing itself affects the brain; it produces 
a decline in sensory and motor abilities and in higher cognitive functions (7). AD 
incidence increases with age and the prevalence doubles approximately every 5 years: 
from 1% in the population from 60 to 64 years old up to a 40% or more in the population 
between 85 to 89 years old (10), as it can be seen in Figure 1 that shows AD distribution 
in the population of the United States. Even aggressive autosomal dominant AD 
mutations do not lead to obvious deficits until the fourth or fifth decade of life (5). 
Numerous mechanisms may protect the young brain against AD, as higher levels of 
growth factors, better energy metabolism and more efficient mechanisms for clearing 
misfolded proteins and repairing cells. The failure of these protective mechanisms can 
contribute to the development of AD. With ageing also increases the prevalence of 
obesity, diabetes and atherosclerosis; illnesses that promote AD through metabolic or 
vascular mechanisms. The inflammatory activity of immune cells, in special 
macrophages and microglia, and of astrocytes increases with ageing and contrary as it 
may seem can promote ageing-related disorders, as it will be seen (5). 
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Figure 1. Distribution in percentages of people with AD in the United States depending on the age 
of the patient. Percentages do not total 100 because of rounding. Adapted from (18). 
5.4.3. Gender 
The female sex may also be a risk factor in developing AD regardless of their longevity, 
as two thirds of the patients are women. A large study exposed that the ApoE ε4 
genotype, the biggest genetic risk factor for AD, may have a stronger association with 
AD in women than in men. It is unknown why this may be the case, but some evidence 
suggests that it may be due to an interaction between the ApoE ε4 genotype and the sex 
hormone estrogen (18). 
Another factor, that may influence in the gender difference could the fact that low 
education is a risk factor for dementia and as in the first half of the 20th century there was 
lower educational attainment in women than in men this could be the reason for a higher 
risk of AD and other dementias in women (18). 
5.4.4. Diabetes 
Brain insulin resistance, an alteration in prediabetes and diabetes mellitus 2, may be 
linked to AD. Patients suffering from diabetes are at a higher risk of developing AD as 
insulin resistance, increased inflammation and impaired metabolism are pathological 
features for both AD and diabetes. Even though the exact mechanism through which 
diabetes causes AD remains unknown, it may include both cerebrovascular and 
noncerebrovascular mechanisms. Such relation has led to some authors to name AD as 
type 3 brain diabetes (2,14). 
Insulin and insulin-like grow factor are thought to regulate some biological processes 
related to memory and learning, in hyperinsulinemia insulin resistance causes the 
activation of glycogen synthase kinase 3β, a key factor in cognitive decline producing 
brain injury as it phosphorylates tau (2,21). 
5.4.5. Toxicants 
The exposition to some organophosphate pesticides and metals (for example copper, 
zinc, iron and manganese) can cause neurotoxicity, neuroinflammation and/or 
neurodegeneration. The “aluminium hypothesis” maintains a relation between aluminum 
exposure (through drinking water, diet and occupation) and both Aβ plaques and NFTs 
(22). 
These environmental factors can initiate or worsen the disease as they increase the 
production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) with 
the subsequent oxidative damage that causes AD, as it will be seen later (23). 
4% 
16% 
37% 
43% 
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5.4.6. Other causes 
The risk of AD may be increased by a low level of education, severe head injury, Down 
Syndrome and vascular risk factors (as shown in Figure 2). However, up to now, it 
remains uncertain whether avoiding life-style risk factors can significantly lower chances 
of suffering the disease, especially in people with genetic risk for AD. It is likely that AD 
predisposing genes interact with other disease genes and environmental factors 
(5,14,15). 
Figure 2. Potential mechanism linking vascular risk factors with vascular cognitive impairment and 
AD. Adapted from (14). 
 
5.5. ALZHEIMER’S DISEASE PATHOGENESIS 
 
Physiopathologically, AD implies changes both neuropathological and in the 
neurotransmitters. There is cortical atrophy, neuronal degeneration and synaptic loss, 
particularly in the parietal and temporal lobes (mainly in the hippocampal formation and 
the amygdala (15)). In case of significant atrophy ventricular growth occurs because of 
the loss of encephalic tissue. 
Figure 3. Key players in the pathogenesis of AD (5). 
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Microscopically, the main characteristics of AD are extracellular senile plaques of 
amyloid deposits, intracellular NFTs of hyperphosphorylated tau, ApoE accumulation 
and cerebral angiopathy (8,11). This changes begin before clinical symptoms emerge 
(18). Oxidative stress, mitochondrial dysfunction and inflammation are also present. The 
representation of all these elements is displayed in Figure 3. 
The Positron Emission Tomography (PET) shows that the first metabolic changes occur 
in the parietal lobe. However, the most serious alterations take place in the hippocampus, 
the cerebral cortex and the basal ganglia as the disease progresses (6). 
This description of the pathogenesis of AD does not pretend to be exhaustive, but aims 
to give an idea of the complexity of this pathology. As it will be seen there are multiple 
neurodegeneration-inducing factors that ultimately lead to the initiation of a common 
signaling cascade of neuronal cell death causing the disease (23). 
5.5.1. Synaptic failure 
AD could be principally a disorder of synaptic failure. In patients with MCI, hippocampal 
synapses begin to occur and the remaining synaptic profiles show compensatory 
increases in size. In mild AD, there is already a reduction of some of the presynaptic 
vesicles and as the disease progresses, synapses are disproportionately reduced 
relative to the number of neurons; this loss is the best correlation with dementia. 
However, in normal aging synaptic loss is also present. The dentate region of the 
hippocampus is particularly affected by the loss of synapses. Subsequent to this loss, 
some signaling molecules important to memory are inhibited (21); such as glutamate, 
acetylcholine and neurotrophins. 
This damage is produced because at high concentrations Aβ oligomers may suppress 
basal synaptic transmission facilitating the endocytosis of the N-methyl-d-aspartate 
receptor (NMDAr) disrupting the release of presynaptic neurotransmitters (21). 
Consequently to this reduction, there is an abnormal prolonged release of glutamate that 
causes excitotoxicity and cell death because an increase in calcium ion influx via the 
NMDAr causes dysregulation of different calcium dependent processes (including 
learning and memory) (22). Aβ oligomers also bind to postsynaptic sites and cause 
synaptic and neuronal loss (24). 
Acetylcholine is a neurotransmitter with an important role in memory and learning. The 
“cholinergic hypothesis” sustains that the loss of cholinergic function in the central 
nervous system contributes significantly to the cognitive decline present in people with 
AD. Acetylcholine is synthetized by choline acetyltransferase and degraded by 
cholinesterase (mainly acetylcholinesterase, AChE, in the brain) (22). Aβ peptide and 
tau bind to acetylcholine receptors impairing the release of acetylcholine from the 
presynaptic terminal (21). This reduction has a quantitative relationship with the number 
of neuritic plaques and the severity of the dementia (6). However, the concentrations of 
the enzymes responsible for the synthesis and degradation of ACh do not drop until the 
later stages of the disease (25). 
Neurotrophins are secreted signaling proteins that promote proliferation, differentiation 
and survival of neurons and glia mediating learning, memory and behavior (3,21). The 
binding of neurotrophins to their receptors protect neurons from damage and reverse 
neurodegeneration. The normal high levels of neurotrophin and their receptors in 
cholinergic neurons in brain are greatly reduced in the late stage of AD (21). 
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5.5.2. Abnormal accumulation of harmful proteins 
A lot of evidence suggests that neurodegenerative diseases, including AD, stem from 
the abnormal accumulation of harmful proteins in the nervous system. In AD, these 
include Aβ, ApoE, the microtubule associated protein tau and the presynaptic protein α- 
synuclein (which is also involved in Parkinson’s disease). It is still a debated issue how 
abnormal accumulation of harmful proteins in nervous system may cause cognitive 
decline (5). 
5.5.2.1. β-amyloid peptide 
All of us make Aβ peptide in the brain: Aβ peptides are natural products of the 
metabolism consisting of 36 to 43 amino acids, with unknown function. Monomers of 
Aβ40 are much more prevalent than the aggregation-prone and damaging Aβ42 species. 
Aβ is highly amyloidogen (prone to aggregation); it accumulates in senile plaques as 
amyloid fibrils, they originate from proteolysis of the amyloid precursor protein (APP, a 
big sized transmembrane protein with neurotrophic and neuroprotective properties) by 
the sequential enzymatic actions of beta-site APP–cleaving enzyme 1 (BACE-1), a β- 
secretase, and a γ-secretase, a protein complex with presenilin 1 at its catalytic core. 
This process also generates AICD, which is a short tail (approximately 50 amino acids) 
that is released into the cytoplasm and targeted to the nucleus signaling transcription 
activation. On the other hand, there is a non-amyloidogenic pathway in which APP 
cleavage is initiated by α-secretase originating a carboxy-terminal fragment that is then 
digested by γ-secretase. This means that amyloid plaques result from the equilibrium 
between Aβ deposition and clearance (21). 
When Aβ concentration is increased by overproduction, defective clearance or 
alterations in transport of the processes that shuttle Aβ across the blood-brain barrier 
(BBB), Aβ self-aggregates into multiple coexisting physical forms: ranging from 
oligomers (2 to 6 peptides soluble) to protofibrils, fibrils and amyloid plaques (insoluble) 
(21). Autophagy, a lysosome-mediated catabolic pathway responsible for turnover of 
long-lived proteins and organelles, seems to have a key role at this point; it protects 
neurons against Aβ and tau induced cytotoxicity (26). 
 
 
 
Figure 4. The amyloid cascade hypothesis. Adapted from (27). 
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The “amyloid cascade hypothesis” (represented in Figure 4) considers the soluble Aβ 
peptides as the primary toxic species in AD. It maintains that Aβ peptide depositions in 
the brain initiate a sequence of events that lead to AD, as: mitochondrial dysfunction, 
aggregation of tau causing NFTs, oxidative stress and synaptic failure. 
There is another theory that explains the neurodegeneration produced in AD. This 
hypothesis came from the idea that soluble oligomers and intermediate amyloids are the 
most neurotoxic forms of Aβ (dimers and trimers of Aβ are toxic to synapses). In fact, the 
severity of the cognitive deficit in AD correlates with the levels of oligomers in the brain, 
not the total Aβ burden. This leaded to the “toxic oligomer hypothesis” because oligomers 
are known to be the most toxic species probably causing neurodegeneration by affecting 
mitochondrial and synaptic function, both early signs of AD (21). 
5.5.2.2. Apolipoprotein E 
The lipid-carrier protein ApoE4 increases Aβ peptide production and impairs Aβ 
clearance. When produced within stressed neurons, ApoE4 is cleaved into neurotoxic 
fragments that destabilize the cytoskeleton and, like intracellular Aβ, impair mitochondrial 
functions as they accumulate there (5,27). 
5.5.2.3. Microtubule associated protein tau 
Tau and α-synuclein can also self-aggregate into pathogenic oligomers and into larger 
inclusions in neurons displacing vital intracellular organelles, known as NFTs and Lewy 
bodies, respectively. By definition, all patients with AD have many plaques and tangles; 
most patients also have Lewy bodies (5). 
NFTs, which are filamentous inclusions in pyramidal neurons, are resistant to chemical 
and enzymatic degradation and can persist in the encephalic tissue long after the neuron 
in which they originated has died and disappeared extracellularly (10,11). The misfolding 
and fibrillation of tau to NFTs can be generated by genetic mutations, posttranslational 
modifications or intracellular environmental changes (28). The major component of the 
tangles is an abnormally hyperphosphorylated and aggregated form of tau. NFTs of tau 
occur in AD and other neurodegenerative disorders termed tauopathies. The number of 
NFTs is a pathologic marker of the severity of AD (21). 
Normally tau (hydrophilic and cationic) is an abundant soluble microtubule-associated 
protein predominantly expressed in the axons of neurons of the central nervous system 
that promotes assembly and stability to the microtubules and vesicle transport. The 
binding of tau to microtubules is mediated by three or four microtubule binding domains 
at the C-terminus of the protein. It has six different isoforms created by alternative 
splicing and is unfolded in native conditions; its function is regulated by posttranslational 
modifications as phosphorylation (mainly), glycosylation, ubiquitination, truncation and 
nitration. The ability of the protein to join the microtubules and perform its action depends 
on the number of phosphates joined to it. In AD, abnormal phosphorylation happens on 
determinate tau residues (Ser2020, Thr205, Ser235 and Ser404) by kinases in post- 
translational modifications. Hyperphosphorylated tau is insoluble, lacks affinity for 
microtubules and self-associates into paired helical filament structures heading to 
abnormal structural changes, disruption of cellular traffic and favoring synapse 
dysfunction and loss. Consequently, enzymes that add and those that remove phosphate 
residues regulate the extent of tau phosphorylation (6,8,11,29). 
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Like Aβ oligomers, intermediate aggregates of abnormal tau molecules are cytotoxic and 
impair cognition but, Aβ oligomers impair synaptic functions whereas fibrillary amyloid 
plaques displace and distort neuronal processes (5). Experimental evidence indicates 
that Aβ accumulation precedes and drives tau aggregation (21). 
5.5.3. Oxidative stress 
Oxidative stress is the result of an imbalance between oxidative systems and antioxidant 
defenses (which can be non-enzymatic, especially dietary antioxidants, or enzymatic), in 
favor of the first ones producing reactive species. This process conduces to the oxidation 
of biomolecules with the consequent loss of their biological functions (30). The chronicity 
of this process leads to important implications in the development of chronic illnesses 
(30): “the free radical theory of aging” maintains that aging is a result of the oxidative 
damage we suffer through life that leads to cell death and organism malfunction (31). 
However, ROS and RNS are produced during normal physiological processes; in fact, 
they are important in the immune response and in cell signaling when in the right 
proportion (22). There are two main compounds that keep free radical levels within the 
physiologically beneficial: antioxidant enzymes (that neutralize reactions against free 
radicals and ROS) and nutrients (that act as co-factors in catalytic activities) (7,22). 
Several biological agents are found to be responsible for the accumulated damage 
oxidative stress produces in ageing, some come from environmental sources (as the 
ones from the exposition to ultraviolet light) and some are produced endogenously (as 
by-products of normal living) (32). 
The effects of ROS are linked with elevated levels of free divalent transition metal ions 
(like iron, copper and zinc) and aluminum, causing neurodegeneration in several ways, 
for instance promoting aggregation of tau and changes in its conformation or 
phosphorylation (21). Oxidative damage can also be a predisposing factor and/or a 
consequence of Aβ deposition, as oxidative stress can induce the production of the Aβ 
producing enzymes: BACE and ϒ-secretase. Moreover, reactive species can also be 
generated in dysfunctional mitochondria and by Aβ in the presence of metal ions (22). 
5.5.4. Mitochondrial dysfunction 
Oxidative stress is closely related to mitochondrial dysfunction. Mitochondria’s are 
primary sites of ATP production, they maintain calcium homeostasis, participate in 
calcium signaling and regulate intrinsic apoptosis (22). Even though all cellular structures 
can be targets for free radicals, the structures that suffer the higher amount of oxidative 
effects are cell membranes (32) and mitochondria is particularly susceptible to this 
changes. Its dysfunction plays an important role not only in brain ageing but also in the 
pathogenesis of neurodegenerative diseases (33). 
Aβ peptide, a potent generator of ROS and NRS, is a key initiator of the mitochondrial 
damage. The dysfunctional mitochondria release oxidizing free radicals that cause 
oxidative stress as they peroxidate membrane lipids and produce toxic aldehydes (21). 
In AD, reduced activities of three mitochondrial enzymes (pyruvate dehydrogenase 
complex, alpha ketoglutarate dehydrogenase complex and cytochrome oxidase) are 
present (27). Carbonyl and nitrated derivatives are also generated because other 
essential proteins are directly oxidized by free radicals. This leads to an increase of 
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membrane permeability to calcium and reduced glucose transport, aggravating the 
energy imbalance (21). 
Due to the mitochondrial dysfunction, there is impaired autophagy that could potentiate 
Aβ deposition. Therefore, early mitochondrial dysfunction and oxidative stress may 
proceed to Aβ overproduction and deposition (22). 
“The mitochondrial theory of aging” maintains that cellular aging is a consequence of 
mutations in the mitochondrial DNA (mtDNA) genome as a result of oxidative damage 
(31). The mitochondria is the principal site of ROS production in cells as the electron 
transfer system constantly generates it and it is kept in balance by different defense 
mechanisms such as antioxidative molecules (as glutathione and vitamin E) and 
antioxidant enzymes (as superoxide dismutase and catalase) (33). Aβ peptide is a 
powerful mitochondrial poison; it especially affects the synaptic pool. In AD, exposure to 
Aβ peptide inhibits important mitochondrial enzymes in the brain and in isolated 
mitochondria: cytochrome c oxidase and alcohol dehydrogenase are specifically 
attacked. Thus, electron transport, ATP production, oxygen consumption and 
mitochondrial membrane potential all become damaged. Due to the accumulation of Aβ 
peptide within structurally damaged mitochondria, mtDNA sustains high levels of 
oxidative damage. This instability and the irreparability of the brain’s mitochondrial 
genome allow the gradual accumulation of mtDNA mutations, producing fragmentation 
of mitochondria and synaptic loss in AD (21). 
5.5.5. Inflammation 
In AD, vascular injury and parenchymal inflammation seem to play an important role in 
the pathogenesis as they perpetuate the cycle of protein aggregation and oxidation in 
the brain (21). 
When Aβ accumulates in the cerebral arterioles it is called cerebral angiopathy and the 
activation of microglia and astrocytes to fight it, may seem a positive response to clear 
protein aggregates through phagocytosis and intracellular degradation; however, 
chronically activated becomes dysfunctional and leads to the production of nitric oxide, 
ROS, pro-inflammatory cytokines (as tumor necrosis factor-α, interleukin-1β and 
interleukin-6) and prostaglandin-E2, which finally cause neuronal death. Furthermore, 
this proinflammatory cytokines produce an increase in tau phosphorylation, APP 
generation and Aβ peptide synthesis through BACE-1 transcription (8). 
Vascular abnormalities impair the supply of nutrients, the removal of metabolic by- 
products and cause microinfarcts. Ischemic disease affects 60 to 90% of patients with 
AD and many cases of dementia are mixed (8,34) therefore it is an important pathogenic 
point to consider. 
 
5.6. ALZHEIMER’S DISEASE DIAGNOSIS 
 
The interest in finding a diagnosis in early phases is growing more and more due to the 
increasing impact of this disease as the population continues to live longer. 
A reference neuropathological criterion is being searched for the definitive diagnosis, 
because amyloid plaques and NFTs are present in people without dementias. This 
means that AD exists in absence of dementia during a period of time, a period that can 
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be called preclinic where there is presence of Alzheimer’s histopathologic changes 
before clinical changes emerge (35). 
In order to standardize the medical practice, it is necessary to follow some criteria. 
Basically, there are two main criteria: the ones from Dubois et al. (36) and the updated 
ones from the National Institute of Neurological and Communicative Disorders which 
reached an agreement with the Alzheimer's Disease and Related Disorders Association 
and developed the criteria NINCDS-ADRDA for AD diagnosis, now called NIA-AA criteria 
(35). 
In one hand, the ones from Dubois et al. (36) are exclusive for the diagnosis of AD. They 
evaluate the gradual affectation in episodic memory by neuropsychological tests and 
analyze the correspondent biomarkers placing subjects in probable AD. The diagnosis 
is only definitive when there is clinical and anatomopathological evidence (at biopsy or 
necropsy) or, when there is clinical and genetic evidence of AD However, this criteria 
need technical and financial resources to obtain a greater probability of certain, 
something that is not available in every single center (35). 
Table 1. Diagnostic criteria for AD from Dubois et al. (36), it requires A criteria plus at least one of B, C, 
D or E. Adapted from (35). 
 
 
 
 
MAIN CRITERIA 
A. Initial and significant episodic memory disorder that includes the 
following characteristics: 
1. Progressive and gradual memory loss for at least six months 
communicated by the patient or by a reliable informant. 
2. Objectify by neuropsychological tests the episodic memory loss. 
3. The episodic memory defect can be isolated or associated with 
other cognitive alterations. 
 
 
 
 
ADDITIONAL 
CHARACTERISTICS 
B. Presence of atrophy in the medial temporal lobe: Volume loss of 
the hippocampus, amygdala and entorhinal cortex, evidenced by 
magnetic resonance. 
C. Alterations of biomarkers in cerebrospinal fluid: Decreased Aβ42 
or increased concentration of total tau or phosphorylated tau, or 
combined. 
D. Characteristic alterations with positron emission tomography: 
Hypometabolism of bilateral glucose in temporal and parietal regions 
or other alterations with radioligands. 
E. Evidence of an autosomal dominant mutation in a first-degree 
relative. 
 
 
On the other hand, NIA-AA criteria are for diagnosing the level of impairment (dementia, 
MCI or normal cognitive functions for the age of the patient). They combine clinical and 
neuropathological patterns and assign diagnoses of “possible”, “probable” and “Probable 
or possible AD with evidence of the Alzheimer’s pathophysiological process” (14,35). 
Actually, these criteria are again under review (14). 
Researchers aim to find early biomarkers for the diagnosis of AD. The use of them must 
consider that biomarkers are different in function of the phase of the disease, for 
instance: at the beginning they can only be found amyloid accumulation biomarkers, as 
the illness develops synaptic dysfunction biomarkers are the ones searched and lastly, 
when the disease is advanced, biomarkers of neuronal loss are the ones examined (35). 
However, there are still problems related with their clinical use, such as insufficient 
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standardization of measurement methods and where the cut points are to separate 
normal levels from pathologic ones. In addition, there are not very sensitive in the early 
phases of the illness and the margin of error is still very big (35). 
Actually, the most common way of diagnose is for exclusion; the diagnosis can only be 
confirmed by microscopical analysis of the tissue obtained by cerebral biopsies or 
necropsies. Therefore, diagnose is based on clinic data through an algorism established 
on the combination of clinical evaluation and radiologic methods. Firstly, it is necessary 
to establish dementia with a clinical exam alterations of consciousness must be absent 
and there must be a beginning between 40 and 90 years old; it is also important to 
evaluate the lack of systemic or encephalic disorders that could explain the deficits of 
memory or cognition (through neuroimaging tests as computed tomography or magnetic 
resonance imaging). This means, that in the first stage of the disorder it is common to 
exclude other causes of dementia by metabolic studies: such as vitamin B12 deficit, 
thyroid dysfunction and electrolyte imbalance (6,11). This exclusion method is capable 
of giving an accurate diagnosis in the 80-90% of the cases then confirmed in the autopsy 
(10). 
 
5.7. ALZHEIMER’S DISEASE TREATMENT 
 
AD treatment pursues to improve quality of life and maximize the functional performance 
by enhancing cognition, mood and behavior. Treatment includes both pharmacological 
and non-pharmacological approaches (37). 
As the exact pathophysiological mechanism of AD is not clear, it hinders the process of 
finding effective treatments (22). In fact, nowadays AD does not have a curative 
treatment, but there are some drugs capable to slow down its progress and control the 
comorbidities associated, especially in early stages. As Aβ peptide and tau aggregation 
are implicated in AD pathogenesis, the therapeutic strategies interfere in this point 
(38,39). There are three groups: cholinesterase inhibitors, glutamate regulators and a 
combination of a cholinesterase inhibitor and a glutamate regulator approved by the FDA 
(20). 
5.7.1. Acetylcholinesterase inhibitors 
They are prescribed to treat symptoms related to memory, thinking and other thought 
processes. There are three different medications from this group: donepezil, galantamine 
and rivastigmine. The first one is approved to treat all stages of AD while the other two 
are only approved for mild-to-moderate stages (38). 
Its pharmacological action consists in the inhibition of the enzyme cholinesterase 
(AChE), increasing levels of acetylcholine (a neurotransmitter involved in learning and 
memory). The function of AChE is to break acetylcholine down so it can be recycled. But 
in AD cells that produce and use acetylcholine are destroyed, therefore an inhibitor of 
this enzyme will promote an increase in acetylcholine concentration and duration of 
action, contributing benefits to the patients (22,38) on cognitive, functional and 
behavioral symptoms of the disease (25). Although they improve neurotransmission and 
relieve symptoms, they lose efficacy over time (21). 
They are usually well tolerated and their side effects include: nausea, vomiting, loss of 
appetite and increased frequency of bowel movements (38). 
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Clinical trials have shown that cholinesterase inhibitors may delay or slow worsening of 
symptoms. However, the combination of the three drugs hasn’t shown any advantage 
respect the administration of one alone, but side effects result in greater frequency (38). 
In the figure below (Table 2) mechanisms, pharmacokinetics and daily doses of the drugs 
approved in this group are described. 
 
Table 2. Pharmacology, pharmacokinetics and daily doses of acetylcholinesterase inhibitors (12,25). 
 
 
GENERIC MECHANISM PHARMACOKINETICS DAILY DOSIS 
Donepezil Non-competitively 
reversibly inhibits 
AChE. It is highly 
selective for it. 
Metabolized in the liver by 
the CYP450 (CYP2D6 and 
CYP3A4) and by 
glucuronosyl transferase 
with extensive first-pass 
metabolism. It binds to 
plasma proteins. 
Once daily before 
going to bed. The 
initial dose is 5 
mg/day with an 
increase in the fourth 
week to 10 mg/day. 
Galantamine Selective reversible 
AChE inhibitor and 
positive allosteric 
modulator of nicotinic 
receptors. 
Metabolized by CYPP450 
isoenzymes (mainly 
CYP2D6 and CYP3A4) in 
the liver, poorly bound to 
plasma-proteins and has a 
terminal elimination of 5 
hours. 
Once daily in the 
mornings for the 
extended released 
capsules and two 
daily for the oral 
solution: in the first 
month 8 mg/day, 16 
mg/day on the 
second and 24 
mg/day on the third if 
there is good 
tolerability. 
Rivastigmine Is a 
pseudoirreversible 
inhibitor of AChE and 
butyrylcholinesterase. 
As it does not have hepatic 
metabolism by CYP450 it 
has low pharmacologic 
interactions, it is 
hydrolyzed by esterases 
and has low plasma- 
protein binding. 
Two doses are 
required daily: initially 
3 mg/day increasing 
gradually until 12 
mg/day. 
 
5.7.2. Glutamate regulators 
Actually, there is only one drug approved in this group: memantine, which is used to treat 
moderate to severe AD (38). 
Glutamate is a neurotransmitter that normally participates in learning and memory 
processes by triggering NMDAr to let calcium into cells (this ion is important for 
information storage). Nevertheless, in AD the abnormal accumulation of harmful proteins 
produces excitotoxicity (overstimulation of NMDAr) causing glutamate excess and 
allowing too much calcium into the nerve cells. Memantine is a drug that acts like a non- 
competitive NMDA antagonist inhibiting the glutamate action (25,38). 
It is administered orally and has an approximate absorption of 100%; moderately bound 
to plasma-proteins suffers a limited metabolism, which leads to inactive metabolites (12). 
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This drug can produce headache, constipation, confusion and dizziness (38). Initially 5 
mg/day are given to the patient; the dose is gradually increased weekly in 5 mg/day, until 
20 mg/day (12). 
5.7.3. Namzaric® 
There is one FDA approved drug (Namzaric®) that combines the cholinesterase inhibitor 
rivastigmine with the glutamate inhibitor memantine. It is approved for moderate-to- 
severe stages in patients taking donepezil hydrochloride 10 mg. Namzaric® both 
prevents the breakdown of acetylcholine in the brain and protects the brain’s nerve cells 
against excess amounts of glutamate (38). 
The recommended dose of Namzaric® is 28 mg/10 mg once daily. It has low binding to 
plasma proteins and suffers from partial hepatic metabolism (12). 
Namzaric® can cause serious side effects, as: increased stomach acidity (raising the 
chance of suffering ulcers and bleeding; being even higher in patients taking aspirins or 
other anti-inflammatories), slow heartbeat, fainting and muscle problems, among others 
(38). 
5.7.4. Behavioral symptoms 
Often patients with AD also suffer from other disorders such as depression, insomnia, 
hallucinations, agitation and aggressiveness. As they have a great impact in the quality 
of life, these disorders can also be treated in a complementary way (20). 
In addition, it is also very important to maintain the patient socialization and to give 
support to the family. These tasks can be facilitated by self-help groups and day care 
centers (6). 
5.7.5. Future developments 
Even though the great efforts of researchers to find early and approachable markers of 
AD, it is still diagnosed very late, when neurological symptoms emerge and 
neuropathology is already in an advanced point. Consequently, two important factors in 
the actual research of AD are early diagnose and prevention (8). 
As we have seen, in AD there are implicated multiple pathogenic factors and the 
medication actually approved does not stop the destruction of nerve cells; therefore the 
ability of these drugs to improve symptoms sooner or later declines as brain cell damage 
progresses (38). 
Right now, there are several clinical trials in progress. They are centered in patients on 
early stages of the disease and use several strategies to remove Aβ from the brain, like: 
immunological approaches (Aβ vaccination), interruption of Aβ formation with drugs 
against ϒ-secretase or BACE and also approaches to prevent tau alterations (fibrillation, 
misfolding and aggregation) (5,10,28). 
The actual anti-AD strategy is based on hitting-one-target drugs. Because of its 
ineffectiveness, more attention is being given in finding multiple-targeted agents to hit 
more than one target involved in AD mechanism. Moreover, it is also interesting to find 
multiple-AD targets in one single structure, as it reduces the risk of drug-drug 
interactions. For this reason, finding natural multi-targeting agents to treat AD is catching 
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increasingly consideration (9) and plant polyphenols are increasingly being considered 
as the starting point to develop this (1). 
 
5.8. FINDING POTENTIAL THERAPEUTIC TOOLS IN THE 
PREVENTION OF ALZHEIMER’S DISEASE 
As AD does not have cure a lot of research is being done to find treatments to delay and 
relieve its symptoms (26). In order to develop prevention, a lot of attention has been 
placed in different lifestyles and dietary regimens that are associated with a reduced 
cognitive decline. Epidemiological data suggests that certain nutrients and foods may 
confer protection against AD, in particular adherence to the Mediterranean Diet (MD) 
shows a lower incidence of MCI and its progression to AD; which means that sufficient 
intake of certain micronutrients and secondary plant metabolites continuously during all 
life-span may prevent disease’s onset (26,33). 
Finding prevention to AD is particularly relevant because the amyloid disease is 
developed during a very long time but its symptoms manifest late in life, when tissue 
damage and functional derangement are already severe and often irreversible (40). 
Different therapeutic approaches are being studied and lately an increased interest has 
been placed into the neuroprotective power of olive oil polyphenols that are present in 
the MD (1). 
5.8.1. The Mediterranean diet 
The term MD refers to the traditional dietary patterns found in some of the Mediterranean 
countries (as Italy and Greece) in the fifties of the twentieth century (3,41). It is associated 
with lower mortality rates and a reduced risk of cardiovascular diseases and cancer, but 
in the last few decades it has also been studied its relation with a reduced incidence of 
neurodegenerative diseases (28). 
The MD is characterized by a high intake of cereals, vegetables, legumes and fruit; 
relevant consumption of seafood; low-to moderate intake of dairy products; low intake of 
red meat and saturated fatty acids; and a regular but moderate intake of wine during 
meals (8,33,42). As olive oil is one ingredient never absent in this diet it was considered 
that it could be one of the elements that could help in the prevention of cognitive decline 
(8). In fact, the European Food Safety Authority and the American Food and Drugs 
Administration have recognized the beneficial effects of polyphenols in olive oil and 
recommend a daily intake of two table spoons (23 g) to prevent the onset of CVD, 
inflammation and to counteract the oxidative stress produced by free radicals (3). 
5.8.2. Olive Oil 
Olive oil is one ingredient never absent of the MD (8) it comes from the olive tree (Olea 
europaea) and is the main source of fat in the MD. Mainly consists of two groups of 
compounds: saponifiable lipids or glycerides (about the 98% of the total composition), 
most of them monounsaturated fatty acids (MUFA) as the oleic acid but also 
polyunsaturated fatty acids (PUFA) mostly linoleic acid and α-linolenic acid. And the 
“minor compounds” (unsaponifiable fraction) that consist from 1 to 2% of the total content 
of an olive oil (43) containing a variety of compounds which despite of their proportion, 
must be taken into consideration because of their activity. These last ones are also the 
responsible of the stability and the organoleptic properties of olive oil and consist of α- 
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tocopherol, several specific phenolic compounds (including phenolic acids, phenolic 
alcohols, lignans, flavones and secoiridoids; being the latter the most abundant and 
typical phenolic components of olive oil) (3,8) and phytoalexins. Phytoalexins are 
secondary plant metabolites that give leaves an unpleasant taste that discourages 
insects of eating them and also gives them defenses against microbial and fungal 
invasions (1). 
Generally, the intake of olive oil ranges from 25 to 50 mL per day in the MD (24,29,42,44), 
consisting of a significant fraction of dietary polyphenols. The main problem related to 
the daily consumption of olive oil is its high caloric value (45). This review will be centered 
in the neuroprotective effects of polyphenols in olive oil, however, to understand 
completely the health benefits of olive oil in AD is necessary to consider all their 
components and not only the phenolic ones (43). 
For a long period, the beneficial neuroprotective effects of olive oil were associated to 
the unsaturated lipids, particularly oleic acid. Nevertheless, it is now known that contrary 
to what was supposed, the phenolic content in olive oil may be the main ingredient 
responsible for the reduced risk of age-related cognitive impairment because if the effect 
of olive oil was attributed to is MUFA content, any type of olive oil or MUFA-rich foods 
would provide the same health benefits (1,29,46). 
Total phenols in olive oil range between 100 (43) and 1000 mg/kg (42). This 
discrepancies are due that their concentration depends on different factors, such as olive 
cultivar (being the Coratina one of the richest olive tree varieties in content of polyphenols 
and the Arbequina one of the poorest), level of maturation at harvest time (early or late: 
early harvests drupes have a longer shelf life as they have higher polyphenol content), 
environmental factors (as altitude or amount of irrigation), extraction conditions and 
systems, oil storage modalities (when exposed to air and light, olive oil phenols oxidize 
and degrade easily) and the processing system employed to produce the olive oil 
(2,8,41). Moreover, there is inaccuracy in the methods that determinate total phenol 
content (47). 
Olive oils can be classified in function of the processing system used to produce them in 
extra virgin olive oil (EVOO), virgin olive oil (VOO), olive oil or pomace oil. VOO is 
obtained from the fruit of the tree exclusively by mechanical or other physical methods 
that do not lead to the alteration of the oil. They do not suffer any treatment other than 
washing, decantation, centrifugation or filtration. If a VOO has a free acidity, expressed 
as g of oleic acid/100 g of olive oil, lower than 0, 8 g is an EVOO (3,41). VOOs with 
acidity superior or equal to 2 in Europe (European Regulation N.1513/0) are submitted 
to a refining process in which some components are lost, mainly phenolic compounds. If 
VOO and refined olive oil are mixed, an ordinary olive oil is produced. The rest of the 
olive drupe and seed after VOO production is processed and submitted to a refining 
process, resulting in pomace olive oil, to which a certain quantity of VOO is added 
(41,46). Consequently, the different types of olive oil do not have the same health 
benefits; being EVOO and VOO the ones associated with a more reduced cognitive 
decline because of their higher polyphenol content (46,47). 
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5.8.3. Polyphenols in olive oil 
5.8.3.1. Content of polyphenols in olive oil 
The phenolic content in olive oil is implicated in defining the bitterness, pungency and 
astringency (28). They are secondary plant metabolites divided into groups in function of 
the number of phenol rings and the structural elements binding in these rings to one 
another. The phenolic compounds in olive oil are: flavonoids, lignans, phenolic acids, 
phenolic alcohols and their secoiridoids precursors (1,2,42). As olive oil contains over 30 
different phenolic compounds this review will only evaluate the last two groups 
mentioned, concretely the polyphenols represented in the figure down below (Table 3) 
as they are the major phenolic compounds in olive oil (47). 
 
Table 3. HT, Tyr, Oleocanthal and OLE present in olive oil. Adapted from (42). 
 
PHENOLIC ALCOHOLS SECOIRIDOIDS 
 
 
 
 
 
 
 
 
Hydroxytyrosol (HT) 
 
 
 
Oleuropein (OLE) 
 
 
Tyrosol (Tyr) 
 
 
(-)- Oleocanthal 
Both HT and Tyr exist in the form of glycosides (bounded to glucose: HT-4-ß-D-glucoside 
and salidroside, respectively) and secoiridoids. Secoiridoids are those molecules formed 
by elenolic acid linked to HT and Tyr. When the elenolic acid is in its glycosidic form - 
bounded to glucose- is called OLE when is bounded to HT and ligstroside when is 
bounded to Tyr. During the processes of crushing and malaxation β-glucosidases 
catalyze the deglycosylation and give the corresponding secoiridoids aglycones. OLE 
and ligstroside aglycones can be additionally hydrolyzed in the gut producing elenolic 
acid and the simple phenols HT and Tyr. HT and Tyr can also from esters with deacetoxy 
elenolic acid and give rise to oleacin and oleocanthal, respectively (43). 
HT and Tyr are most prevalent in the olive fruit and OLE in the leaves (3). In a VOO, 
almost the half of the total phenolic content are conjugated forms as OLE and ligstroside 
aglycones, while free forms of Tyr, HT and their secoiridoid derivatives are approximately 
a 30% (41). OLE concentration is reduced through chemical and enzymatic reactions 
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during the maturation or olive oil processing, producing an increase on the principal 
degradation product of OLE, HT (39,48). 
HT can be obtained by two possible ways: and exogenous one (when natural products 
that contain HT or its precursors are ingested) or an endogenous one (as a product of 
the oxidative metabolism of dopamine through monoaminooxidase and aldose/aldehyde 
reductase). HT is present at very low concentrations in fresh olive oil and may increase 
with olive oil aging because of the degradation of OLE. To obtaining HT in an exogenous 
way, OLE must suffer a double hydrolysis; firstly during olive oil maturation and storage, 
and then in the gastrointestinal tract (3,42,43). In the same way as HT, Tyr can also be 
obtained exogenously or be endogenously synthesized as byproducts of tyramine 
through the same enzymes as HT. However, the endogenous pathways of their 
synthesis are minor in normal conditions but gain importance after ethanol consumption 
(43). 
Oleocanthal is present mainly in freshly pressed EVOO and is the responsible for the 
bitter taste that produces a burning sensation at the back of the throat (28,42). 
5.8.3.2. Olive oil polyphenols bioavailability 
The bioactivity of plant polyphenols depends on the absorption and metabolism of these 
products, the vehicle of administration has an important role on its bioavailability too 
(30,42). 
Most of the dietary polyphenols are in glycosylated derivate forms in food and to be 
bioactive in the human body must suffer from intestinal biotransformation by digestive 
enzymes and microbiota metabolism. These transformations (deglycosylation by gastric 
acid and hydrolysis by β-glucosidase in small intestinal epithelial cells) are very important 
to ensure some of the beneficial effects of polyphenols before their metabolism and 
excretion (1). 
Humans are able to absorb natural phenols as after their ingestion they appear in plasma 
and urine (HT and Tyr are absorbed in a dose-dependent manner), nevertheless their 
bioavailability is poor due to an incomplete intestinal absorption and to a rapid 
biotransformation that favors their urinary excretion (1). 
Polyphenol aglycones diffuse passively through membranes and are better absorbed 
than their glycated parts; pass from the enterocyte to the lymph and to the blood stream 
(1). To exert their pharmacological effects they need to cross the BBB and achieve 
enough concentration in the brain (22); despite their permeability through the BBB their 
concentration in brain it is reported to be very low (1). 
As many non-polar products they are exposed to Phase I and Phase II metabolism 
originating sulphated, hydroxylated and glucuronide derivatives as well as their 
degradation products that favor their excretion and provide them new biological activities; 
these metabolites can also reach the brain and contribute to the neuroprotection (1). For 
example, the free portion of HT in plasma is extremely low; around 98% is conjugated 
as sulfates (higher doses) and glucuronides (low doses) (42). 
In conclusion, polyphenols are absorbed from the intestine and distributed through the 
blood flow to the whole organism. There is evidence that OLE, HT, Tyr and Oleocanthal 
are able to cross the BBB (1,2,40,42). 
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The specific microorganisms in the gut also influence the bioactivity of polyphenols. 
When polyphenols reach the colon they are metabolized by gut microbiota to low- 
molecular weight compounds; therefore the colonic microflora can metabolize and 
chemically modify polyphenols (2) and be in part responsible of their systemic effects 
(30). However there is still a little known about this impact (40). A resume of all this 
process is included in Figure 5. 
 
 
 
 
 
Figure 5. Absorption and metabolism of polyphenols in animals (49). 
Some conditions may improve the poor bioavailability of these products; for instance, 
OLE stability can be increased both in the stomach and in the intestine if it is ingested 
with the meal (40). Therefore, recommendations of daily intakes of olive oil polyphenols 
to obtain neuroprotective effects need to consider functional active doses and their 
bioavailability (33). 
Due to the reduced bioavailability of plant polyphenols in olive oil, some solutions are 
under study; the most investigated one is the encapsulation inside nanoparticles (1) 
which improves both stability and bioavailability of the molecules (40). Emulsions are 
considered to be one of the most popular forms of encapsulation and delivery due to the 
maintenance of chemical stability and the controlled release of the encapsulated 
molecules (50). For instance, OLE was found to enter β-cyclodextrin particles with its 
phenolic portion, this protected it from oxidation at the same time it increased its solubility 
(40). Nutraceuticals, enriched olive oils in polyphenols with concentrations much higher 
than those found in their natural forms, are also an emerging path (42). These olive oils 
with higher phenolic content are more bitter and greener than those with low phenolic 
content (46). But before developing these products is important to use appropriate 
analytical methods to estimate the polyphenol content that produces beneficial effects in 
order to standardize the concentration of these products (42). 
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5.8.4. Polyphenols activity: Where do polyphenols act in 
Alzheimer’s disease? 
Experimental evidence has demonstrated that the phenolic compounds present in olive 
oil are, at least partly, responsible for the beneficial effects arising from the consumption 
of this oil. Olive oil phenols possess different biological properties as antioxidant, 
antimicrobial, anti-inflammatory, antidiabetic, antitumoral, cardioprotective and 
neuroprotective (3,44). 
Polyphenols in olive oil do not simply act on a single step of AD, they seem to modify 
several different aspects of the biological and functional features of the cells and tissues 
where aggregation takes place (40): its mechanism involves interactions that are 
important in the normal functioning of cells (51). 
Most of the studies that investigate where do polyphenols act in AD use cell culture 
experiments making it difficult to extrapolate in vitro data to in vivo conditions (33); for 
this reason is always necessary to verify if the discoveries can be translated into practical 
clinical recommendations (42). This is because the exact way polyphenolic compounds 
exert their neuroprotective effect is still incompletely understood. However, it is known 
that their mechanism on cells is not only through their antioxidant activity (for which they 
are most famous) but also through different pathways such as signaling cascades, anti- 
apoptotic processes and synthesis/degradation routes that may not occur in humans in 
the same way as on cells (39). 
Different studies had been carried out to test the efficiency of polyphenols in AD by 
administrating to rodent’s diet supplementation olive oils rich in polyphenols. In general 
those researches jump into conclusion that EVOO improves learning and behavioral 
deficits associated with aging and AD (26). Such as the one of Ah Young Lee et al. (34) 
in which it was investigated the effect of oils with different fatty acid composition on 
learning and memory function determined in behavioral tests (34). Or the one from 
Cristina Grossi et al. (26) that provides a compelling evidence that OLE aglycone intake 
improves the cognitive performance of young and middle-aged rats, converting OLE in 
a useful compound to prevent AD, or at least, to delay the appearance and to reduce the 
severity of its symptoms (26). In fact, there are plenty of studies that provide some 
evidence in this field (39). However, there are still many issues unresolved, as: dose, 
treatment duration and food and drink interactions, among others (22). 
Next, olive oil polyphenols effects on AD pathogenesis are going to be exposed in the 
same way as AD mechanism in the previous sections has been presented. 
5.8.4.1. Synaptic failure 
Olive oil is capable of inhibiting AChE by formatting strong hydrogen bonds and multiple 
hydrophobic interactions with it. This interaction increases acetylcholine levels, an 
important neurotransmitter in maintaining cognitive functions like learning and memory, 
helping to maintain the normal synaptic activity (22). Many phenolic compounds in olive 
oil had been investigated for their AChE inhibitory activity, but the identification of these 
compounds has not been precisely determined yet (52). The ability of polyphenols to 
block NMDAr and enhance the synaptic functioning has not been given enough attention, 
and more research is needed to be done before jumping to any conclusions (22). 
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However, olive oil polyphenols are known to improve the synaptic failure present in AD; 
for instance, as Oleocanthal, HT, Tyr and OLE alter the oligomerization state of Aβ, they 
protect neurons from the Aβ oligomers induced synaptic deterioration as they reduce 
their binding to synapses (1,24). Moreover, polyphenols in olive oil are able to increase 
neurotrophins levels and the expression of their receptors as the intraperitoneal 
administration of HT and OLE increase levels in brain areas of neurotrophins protecting 
neurons from the damage caused by their deficits (3). 
5.8.4.2. Abnormal accumulation of harmful proteins 
Plant polyphenols act like amyloid inhibitors; they have different mechanisms to redirect 
the aggregation towards a path where no oligomeric or nontoxic oligomeric intermediates 
are formed. In some cases they can also disaggregate performed fibrils (40). 
Nevertheless, polyphenols and their glycosides affect amyloid aggregation in a different 
way: amyloid oligomers are remodeled by the aglycones by rapid conversion into large 
off-pathway aggregates, whereas the glycated forms rapidly dissociate into soluble 
disaggregated peptides molecules the amyloid oligomers (1,2). 
Oleocanthal enhances Aβ clearance from the brain via up-regulation (increasing 
expression) of P-glycoprotein and LDL lipoprotein receptor related protein-1 (LRP1), 
which are major Aβ transport proteins at the BBB (29). It also inhibits the formation of 
NFTs as it interacts covalently through two aldehyde groups with the lysine residues of 
a tau fragment inducing conformational modifications that interfere with protein 
aggregation (1,42). 
OLE forms a noncovalent complex with Aβ or its oxidized form (9,48) producing the 
precipitation of Aβ into amorphous aggregates without toxicity that finally evolve into non- 
harmful protofibrils. It also prevents and reduces the growth of toxic oligomers and 
plaque deposition (40). It is moreover capable to hinder the aggregation of tau into NFTs 
(1); in fact OLE, OLE aglycone and HT do inhibit tau aggregation at the same level as 
methylene blue (a reference compound for tau anti-aggregation) (53), but the OLE 
aglycone proved to be more effective inhibiting tau aggregation than OLE or HT (22). 
OLE induces autophagy (shown by the increase of autophagic markers and lysosomal 
activity) protecting neurons from Aβ-induced cytotoxicity (2,26,40). Because all of these, 
OLE improves learning and memory (3) as some studies in rodents have shown. For 
instance, the one of Grossi et al. (26) showed that mice dietary supplementation with 
OLE aglycone improved memory deficits as it reduced Aβ40 and Aβ42 levels as well as 
it reduced plaque size and de novo deposits and favored the already performed plaque 
disassembly (26). 
In conclusion, Oleocanthal, OLE, HT and Tyr are able to interfere in the aggregation path 
of Aβ binding to the aggregation molecules, eviting the appearance of toxic species and 
favoring the formation of non-toxic disordered aggregates protecting neuronal cells 
against Aβ and tau induced toxicity (2,54). 
No articles related with polyphenols activity towards the aggregation path of ApoE were 
found during the development of the present study. 
5.8.4.3. Mitochondrial dysfunction 
Due to the mitochondria-related oxidative damage previously explained, a polyphenol 
supplementation would not only help in the process of harmful accumulation of proteins 
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but also, as olive oil polyphenols are excellent antioxidants, would enrich mitochondrial 
membranes with less oxidizable fatty acids and reduce lipid peroxidation (31). 
Diets with high levels of PUFA are associated with higher levels of lipid peroxidation and 
DNA double-strand breaks compared to MUFA-based diets. The diet fat profile 
influences membranes, including the mitochondrial one, and therefore a low diet in PUFA 
and rich in antioxidants may help in the prevention of developing AD as it reduces 
reactive species and consequently mitochondrial dysfunction (31). 
HT promotes mitochondrial biogenesis as it increases the activity and protein expression 
of mitochondrial complexes I, II, III and V, enhances oxygen consumption and reduces 
free fatty acid contents in the adipocytes helping in the prevention of AD reducing 
mitochondrial dysfunction (22). 
5.8.4.4. Oxidative stress 
MD polyphenols are most studied for their antioxidant activity; they are known to be 
excellent antioxidants both as ROS scavengers (thanks to the aromaticity of their 
phenolic rings) and transition metal chelators (8,9). Polyphenols in olive oil also increase 
antioxidant molecules, such as HDL cholesterol (41) and directly act on enzymes, 
proteins, receptors and several types of signaling as well as interfere in the biochemical 
homeostasis (1). This antioxidant activity is not only beneficial in the prevention of AD, 
but is also useful in the prevention of cardiovascular diseases as it helps to protect LDL 
from oxidative damage (42). 
Oxidative stress plays an important role both in aging and in age-related diseases (22). 
As the brain has high metabolism, oxidative stress occurs in its neural tissue; in fact, is 
considered to cause the initiation and propagation of neurodegenerative diseases (23). 
The brain is especially sensitive to oxidative damage because its high content of PUFA 
(constituents of neuronal cell membranes, which are easily peroxidizable substrates), its 
low level of endogenous antioxidant enzymes and moreover, its high oxygen 
consumption rate (54). That particular evidence of oxidative stress in AD brains indicates 
the potential role that antioxidants, such as phenolic compounds from diet, could play in 
its prevention and control. Although dietary phenolic compounds are good antioxidants 
in vitro, in vivo such effects may be indirectly mediated through the activation of some 
pathways and not their intrinsic antioxidant activity (42). 
Figure 6. Dual neuroprotective model of HT: it directly neutralizes free radicals and indirectly induces 
the endogenous antioxidant defense systems in cells (55). 
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HT prevents from induced oxidative stress in cells through two different mechanisms. On 
one hand, as it has a small size and a lipophilic character is able to pass through the 
plasma membrane, get inside cells and directly stabilize ROS generated during oxidative 
stress. And on the other hand, is also capable of increasing endogenous defense 
systems by inducing phase II detoxifying enzymes (such as increasing the expression of 
manganese-superoxide dismutase) via nuclear factor 2 (Nrf2) activation (40,42,55) as 
represented in Figure 6. 
Nrf2 is regulated by its interaction with Keap1 that directs the transcription factor for 
proteasomal degradation of Nrf2. When one or more critical cysteine residues of Keap1 
are modified (by oxidative stress for instance) Nrf2 escapes from Keap1 inhibition and is 
translocated to the nucleus where it interacts with the protein small Maf (sMaf) forming 
Nrf2-sMaf heterodimers that bind to the antioxidant responsive elements (ARE) to 
regulate the gene expression of several phase II detoxifying enzymes. HT is able to 
induce the Nrf2 translocation to the nucleus and to increase antioxidant enzymes 
expression (42). 
Moreover, polyphenols act like caloric restriction mimickers. Caloric restriction is capable 
of reducing the risk of suffering age-associated diseases and can extend lifespan. 
Nevertheless, caloric restriction is difficult to be maintained for long periods. Plant 
polyphenols are able to mimic caloric restriction effects by affecting their cellular targets, 
mainly through the activation and increased levels of sirtuins. Sirtuins are involved in 
lifespan and metabolism regulation, Sirt1 protects cells against oxidative stress and DNA 
damage as it activates Nrf2 and reduces inflammation (2). 
Tyr is also studied for its potent activity as antioxidant; however, HT and Tyr have 
different antioxidant profiles as they act through different mechanisms. This could be due 
to the fact that they have different chemical structures: HT has two OH groups and Tyr 
only has one (3). 
OLE and its aglycone (40), similarly to HT, increase superoxide dismutase, catalase and 
glutathione peroxidase activities in brain aged rats (antioxidant defenses) (42). 
The phenolic content of olive oil modulates the degree of lipid and LDL oxidation; being 
lower after an ingestion of high content phenolic olive oil, this represents a beneficial 
effect in the prevention of cardiovascular diseases. It is therefore important to have a 
high intake of antioxidants in the diet because they are key factors in the pathogenesis 
not only of neurodegenerative disorders but also of all kind of oxidative stress related 
disorders (41). 
5.8.4.5. Inflammation 
In olive oil, both MUFA fat and phenolic compounds have anti-inflammatory properties; 
in fact, EVOO rich in polyphenols has shown in some studies to be more effective in 
lowering LTB4 and TXB2 (important metabolites in inflammation) than refined olive oil 
with lower phenolic content (41). 
Oleocanthal can display a non-steroidal anti-inflammatory activity with similar properties 
to ibuprofen (28): it is capable to inhibit COX-1 and COX-2 activity (9,42). During the 
development of the disease there is overproduction of prostaglandins that contribute to 
the neuropathology, thus the external support with natural phenols that are able to inhibit 
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the enzymes responsible of the production of prostaglandins (COX-1 and COX-2) may 
be helpful in the prevention and treatment of AD (40). 
Diet supplementation with OLE produced migration of microglia to the amyloid plaques 
favoring the phagocytosis of the amyloid deposits and in addition, reduced the astrocyte 
reaction. In other words, it helped reducing the inflammation present in AD (2,26,40). 
Moreover, EVOO polyphenols, in particular OLE, are able to regulate the mTOR 
pathway, whose downregulation leads to FOXO3 activation with the subsequent 
transcription of homeostatic genes that favor longevity and reduce inflammatory genes. 
mTOR is one of the most potent upstream regulators of autophagy; when autophagy is 
genetically inhibited degenerative modifications are produced as in AD. As olive oil 
polyphenols are able to participate at this level this is one more beneficial effect against 
the development of AD (2). 
All this data from different studies supports the protection of olive oil against 
neurodegeneration (2). The results of clinical trials sometimes are not definitive and in 
some cases may also seem contradictory. This is probably a result of the many different 
factors (not only diet-related) involved in the pathogenesis and clinical progression of 
AD, as well as the difficulty of controlling that people follow precisely the planned diet for 
long time periods. Also, several biological interactions might occur between nutrients and 
lead to synergistic effects and finally, it might also be due to the extreme variability in 
individuals (7,40). However, there is considerable evidence from animal and first human 
studies that suggest the neuroprotective effects of polyphenols in preventing or even 
reversing changes in cognitive and motor functions (33). 
5.8.5. Epidemiological studies with olive oil and its polyphenols 
Epidemiological studies have an important role as they direct the attention towards 
observed phenomenon’s opening new territories for experimental research (22). Some 
of the most important population-based studies with olive oil are the “Three-City Study”, 
PREDIMED, PREDIMED-NAVARRA and EUROLIVE. 
The “Three-City Study” was a multi-center cohort study, produced in three French cities 
and designed to estimate the risk of dementia and cognitive impairment. This study 
showed a lower incidence of cognitive deficit in those subjects that used olive oil 
moderately (just for cooking) and intensively (for dressing and cooking) in contrast to 
those who never used it (2,50,56). 
The results of this study where confirmed by two multicenter, randomized, controlled 
trials: PREDIMED (PREvención con DIeta MEDiterránea) and PREDIMED-NAVARRA, 
they were carried out in Spain with people at high cardiovascular risk. PREDIMED was 
a prevention trial originally designed to test the long-term effects of the MD on the 
incidence of cardiovascular diseases, but some readjustments were made and it finally 
also tested the cognitive performance. It showed that an intervention with a MD enriched 
in EVOO improved cognition, and that this result was mainly due to the EVOO phenolic 
content. It also suggested that the consumption of EVOO is associated with a reduced 
risk of cardiovascular disease (2,57). 
PREDIMED-NAVARRA investigated after 6, 5 years of nutritional intervention diet–gene 
interaction across different genetic profiles and the effect on cognition; it was a 
randomized trial in which subjects were divided in three groups depending on the diet. It 
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revealed that cognitive performance was superior for non-ApoE4 and for ApoE4 carriers 
of the MD groups compared to controls. This lead to the conclusion that an intervention 
with MD modulates the effect of genetic factors on cognition and this effect might be 
greater in subject’s carriers of a more favorable genetic profile (1,2). 
EUROLIVE (effect of olive oil consumption on oxidative damage in European 
populations) was a large, crossover, multicenter, clinical trial carried out in 200 
individuals from five European countries. Subjects where divided in three groups 
depending on the phenolic content of the olive oil they daily took. It was seen a linear 
decrease of the total cholesterol/HDL-cholesterol ration and of oxidative stress markers 
with the increase of the phenolic content of olive oil (2,41). 
These epidemiological studies corroborate the hypothesis that polyphenols in the MD 
are capable of reducing the risk of suffering from age related neurodegeneration. 
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6. CONCLUSIONS 
 
AD is characterized by extracellular senile plaques with amyloid-beta peptide deposits 
and intracellular neurofibrillary tangles with hyperphosphorylated tau-protein aggregates, 
which ultimately cause neuronal death (58). These changes begin years before clinical 
symptoms emerge and when they do, there are multiple stages. 
As the actual therapeutic targets only provide symptomatic benefits and modifiable 
lifestyle-related factors are associated with cognitive decline, it seems reasonable 
directing research towards dietary prevention. MD is associated with lower rates of 
cognitive decline, more concretely the polyphenols present in olive oil seem to have an 
important role at this point. The actual evidence of the effective activity of natural phenols 
in dementia prevention is still limited, however epidemiological and clinical evidence is 
increasingly available. Yet, what is clear is that the best option rather than single nutrients 
is a balanced diet, caloric restriction, physical activity and adequate rest (2). 
Polyphenols in olive oil are known to act in several steps of AD pathogenesis. They are 
able to inhibit AChE rising levels of the neurotransmitter acetylcholine and improving 
synapses, they are also capable of redirecting the aggregation towards a path where no 
oligomeric or nontoxic oligomeric intermediates are formed; even they can also 
disaggregate performed fibrils. Moreover, they enrich mitochondrial membranes with 
less oxidizable fatty acids avoiding their dysfunction and reduce the oxidative damage 
as they supplement the endogenous antioxidant defense system. Finally, they also have 
an anti-inflammatory activity, favor the phagocytosis of amyloid deposits and reduce the 
astrocyte reaction. The major polyphenols present in olive oil are Tyr, HT, OLE and 
Oleocanthal; yet not every polyphenol is able to act in every step of the pathogenesis. 
Even though research in polyphenols has been rapidly growing, there is still necessary 
further research to be done; as AD is a complex disease and there are some pieces of 
the puzzle still missing. To help developing diagnoses and treatment is necessary to 
stablish the precise mechanisms involved in the onset and progression of the disease, 
as well to develop early and accurate biomarkers. Moreover, some of the polyphenols 
molecules display different in vitro and in vivo activities so it is always necessary to verify 
the discoveries in living organisms. 
The effective daily dose of olive oil polyphenols to be administered to humans to obtain 
health benefits is still lacking, however the amount of polyphenols present in foods is not 
adequate to ensure daily doses to get short term effects: it is necessary the continuous 
assumption of these in long term or to increase the intake of these substances by 
assuming specific nutraceutical products (like an EVOO enriched in polyphenols). In 
addition, some solutions are rising up to increase the limited bioavailability of plant 
polyphenols and help to obtain the neuroprotective effect such as polyphenol 
encapsulation inside nanoparticles. 
The protection provided by olive oil polyphenols goes beyond their known antioxidant 
activity, therefore to understand their exact mechanism it is important to consider all of 
their properties. In fact, it is thanks to their several effects why they are interesting as 
potential compounds to combat AD; because of their multi-functionality. Olive oil 
consumption, particularly EVOO because of its higher phenolic content, with a controlled 
intake, may help in the prevention of AD. 
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